indobufen has been researched along with Cardiovascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alessandrini, P; Bon, GB; Bucciarelli, T; Ciabattoni, G; Cipollone, F; Costantini, F; Davi, G; Mezzetti, A; Minotti, G; Patrono, C | 1 |
| Andriani, A; Chiappetta, MG; Gregori, G; Mosiello, G; Rinaldi, P | 1 |
1 trial(s) available for indobufen and Cardiovascular Diseases
| Article | Year |
|---|---|
[Clinico-hematological evaluation of 57 patients undergoing antiaggregant treatment with indobufen].
Topics: Cardiovascular Diseases; Female; Humans; Isoindoles; Male; Middle Aged; Phenylbutyrates; Platelet Aggregation Inhibitors; Time Factors | 1990 |
1 other study(ies) available for indobufen and Cardiovascular Diseases
| Article | Year |
|---|---|
In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia.
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Cyclooxygenase Inhibitors; Dinoprost; Female; Humans; Hypercholesterolemia; Isoindoles; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Phenylbutyrates; Platelet Activation; Platelet Aggregation Inhibitors; Reactive Oxygen Species; Thromboxane B2; Vitamin E | 1997 |